- Home
- DSM vs STXS Comparison
DSM vs STXS Comparison
Compare DSM & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- STXS
- Stock Information
- Founded
- DSM 1989
- STXS 1990
- Country
- DSM United States
- STXS United States
- Employees
- DSM N/A
- STXS N/A
- Industry
- DSM Investment Managers
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DSM Finance
- STXS Health Care
- Exchange
- DSM Nasdaq
- STXS Nasdaq
- Market Cap
- DSM 304.0M
- STXS 275.9M
- IPO Year
- DSM N/A
- STXS 2004
- Fundamental
- Price
- DSM $6.02
- STXS $2.97
- Analyst Decision
- DSM
- STXS
- Analyst Count
- DSM 0
- STXS 0
- Target Price
- DSM N/A
- STXS N/A
- AVG Volume (30 Days)
- DSM 161.7K
- STXS 537.5K
- Earning Date
- DSM 01-01-0001
- STXS 11-11-2025
- Dividend Yield
- DSM 3.97%
- STXS N/A
- EPS Growth
- DSM N/A
- STXS N/A
- EPS
- DSM N/A
- STXS N/A
- Revenue
- DSM N/A
- STXS $31,806,000.00
- Revenue This Year
- DSM N/A
- STXS $30.98
- Revenue Next Year
- DSM N/A
- STXS $49.86
- P/E Ratio
- DSM N/A
- STXS N/A
- Revenue Growth
- DSM N/A
- STXS 33.94
- 52 Week Low
- DSM $4.69
- STXS $1.54
- 52 Week High
- DSM $6.05
- STXS $3.59
- Technical
- Relative Strength Index (RSI)
- DSM 59.37
- STXS 46.32
- Support Level
- DSM $5.93
- STXS $2.96
- Resistance Level
- DSM $6.07
- STXS $3.15
- Average True Range (ATR)
- DSM 0.05
- STXS 0.14
- MACD
- DSM -0.00
- STXS -0.03
- Stochastic Oscillator
- DSM 64.29
- STXS 6.19
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.